Tacrolimus

Generic Name
Tacrolimus
Brand Names
Advagraf, Astagraf, Envarsus, Modigraf, Prograf, Protopic, Tacforius
Drug Type
Small Molecule
Chemical Formula
C44H69NO12
CAS Number
104987-11-3
Unique Ingredient Identifier
Y5L2157C4J
Background

Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condi...

Indication

Immediate-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. Extended-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric ...

Associated Conditions
Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Oral Lichen Planus, Psoriasis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Atopic Dermatitis, Vitiligo, Moderate Atopic dermatitis
Associated Therapies
-
Clinical Trials
Related News

FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients

Phase 3
Completed
Conditions
Myasthenia Gravis
Interventions
Drug: placebo
Drug: tacrolimus
First Posted Date
2006-03-31
Last Posted Date
2014-08-25
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
80
Registration Number
NCT00309088

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

First Posted Date
2006-03-17
Last Posted Date
2013-08-14
Lead Sponsor
University of California, San Francisco
Target Recruit Count
5
Registration Number
NCT00304018
Locations
🇺🇸

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Tacrolimus Treatment of Patients With Idiopathic Focal Segmental Glomerulosclerosis

Not Applicable
Withdrawn
Conditions
Focal Glomerulosclerosis
Interventions
Drug: Tacrolimus
First Posted Date
2006-03-14
Last Posted Date
2012-02-09
Lead Sponsor
Nanjing University School of Medicine
Registration Number
NCT00302536
Locations
🇨🇳

Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, China

Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy

Not Applicable
Completed
Conditions
Idiopathic Membranous Nephropathy
Interventions
Drug: Tacrolimus
First Posted Date
2006-03-14
Last Posted Date
2012-02-03
Lead Sponsor
Nanjing University School of Medicine
Target Recruit Count
16
Registration Number
NCT00302523
Locations
🇨🇳

Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, China

🇨🇳

Research Institute of Nephrology, Jinling Hospital, Nanjing, Jiangsu, China

Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

First Posted Date
2006-03-13
Last Posted Date
2012-10-02
Lead Sponsor
University of California, San Francisco
Registration Number
NCT00301912
Locations
🇺🇸

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

First Posted Date
2006-03-13
Last Posted Date
2017-10-12
Lead Sponsor
University of California, San Francisco
Target Recruit Count
7
Registration Number
NCT00301951
Locations
🇺🇸

UCSF Comprehensive Cancer Center, San Francisco, California, United States

Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients

Phase 4
Completed
Conditions
Immunosuppression
Interventions
Drug: Tacrolimus
Drug: combination therapy
First Posted Date
2006-03-06
Last Posted Date
2015-05-28
Lead Sponsor
Newark Beth Israel Medical Center
Target Recruit Count
150
Registration Number
NCT00299221
Locations
🇺🇸

Mt. Sinai Cardiovascular Institute, New York, New York, United States

🇺🇸

Newark Beth Israel Medical Center, Newark, New Jersey, United States

Pre-transplant Assessment of Tacrolimus Blood Level Concentration, as a Predictor of Tacrolimus Dose Requirements After Kidney Transplantation

Phase 4
Completed
Conditions
Kidney Transplantation
Transplantation
First Posted Date
2006-02-28
Last Posted Date
2011-06-20
Lead Sponsor
Janssen-Cilag Pty Ltd
Target Recruit Count
89
Registration Number
NCT00297310

To Compare the Efficacy and Safety of a Therapy of Tacrolimus With Sirolimus or MMF in Kidney Transplantation.

Phase 3
Completed
Conditions
Kidney Transplantation
Interventions
Drug: Tacrolimus
First Posted Date
2006-02-27
Last Posted Date
2014-09-01
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
634
Registration Number
NCT00296361

Comparing Efficacy and Safety of Steroid Withdrawal With Tacrolimus and MMF With Induction in Children After Kidney Transplantation

First Posted Date
2006-02-27
Last Posted Date
2015-06-26
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
198
Registration Number
NCT00296348
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy